Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Last trade$0.8031
Day change+$0.0004 (+0.04%)
Day range$0.803 – $0.85
Volume477,021
Market cap$81M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$80.66M
Price / earnings
—
Price / book
4.62×
Price / sales
2.68×
EV / sales
2.33×
EV / EBITDA
-3.31×
Profitability
Earnings per share
-$0.23
Return on assets
-42.44%
Return on equity
-134.97%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.42×
Quick ratio
0.95×
Cash ratio
0.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.5M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for STXS, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$7.67M
$6.29M
$8.64M
$7.46M
$8.8M
$7.47M
$6.34M
$9.2M
Cost of revenue
$3.18M
$2.5M
$4.32M
$3.36M
$4.22M
$3.41M
$3.12M
$5.1M
Gross profit
$4.49M
$3.79M
$4.33M
$4.1M
$4.58M
$4.06M
$3.22M
$4.1M
Selling, general and administrative
$6.66M
$7.38M
$7.27M
$8.11M
$7.27M
$7.64M
$8.05M
$7.99M
Research and development
$2.39M
$2.4M
$2.71M
$2.55M
$1.78M
$2.35M
$2.79M
$2.45M
Total operating expenses
$9.05M
$9.78M
$9.98M
$10.66M
$8.56M
$9.99M
$10.84M
$10.44M
Operating income
-$4.57M
-$5.98M
-$5.65M
-$6.56M
-$3.98M
-$5.93M
-$7.63M
-$6.35M
Interest expense
$0
$0
$118K
$91K
$0
$0
$114K
$150K
Income before taxes
-$4.47M
-$5.86M
-$5.53M
-$6.46M
-$3.83M
-$5.82M
-$7.52M
-$6.19M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.47M
-$5.86M
-$5.53M
-$6.46M
-$3.83M
-$5.82M
-$7.52M
-$6.19M
Net income attributable to common shareholders
-$4.78M
-$6.17M
-$5.85M
-$6.79M
-$4.14M
-$6.14M
-$7.84M
-$6.52M
EBITDA
-$4.16M
-$5.59M
-$5.25M
-$6.17M
-$3.58M
-$5.56M
-$7.26M
-$6.02M
Basic earnings per share
-$0.05
-$0.06
-$0.06
-$0.07
-$0.05
-$0.07
-$0.09
-$0.08
Diluted earnings per share
-$0.05
-$0.06
-$0.06
-$0.07
-$0.05
-$0.07
-$0.09
-$0.08
Recent news
Company coverage with links to the original publishers.
Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption.
Stereotaxis announced a definitive agreement to acquire Robocath, a developer of robotic technologies for interventional cardiology and neurointerventions. The acquisition is expected to contribute approximately $2 million in annual revenue in the first year and reach breakeven by year three. The deal includes a $20 million upfront payment with up to $25 million in contingent payments tied to regulatory and commercial milestones, with closing expected in mid-2026. Stereotaxis plans to pursue regulatory submissions in the US and Europe within two years and expand into electrophysiology applications.
Stereotaxis announced it will release its 2025 fourth quarter and full year financial results on March 9, 2026, followed by a conference call at 4:30 p.m. ET to discuss results and corporate developments. The company is a leader in surgical robotics for minimally invasive endovascular intervention.
Stereotaxis will release its Q3 2025 financial results on November 11, 2025, and host a conference call at 4:30 p.m. ET to discuss company results and developments.
Stereotaxis, a leader in surgical robotics, will release its Q1 2025 financial results on May 12, 2025 and host a conference call to discuss the company's performance and developments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.